Petrelintide

The verdict

Our read at a glance.

Whether amylin agonism can deliver GLP-1-comparable weight loss with materially better tolerability, and whether the company-reported phase 2 numbers hold up in peer review and in phase 3.

The signal

In the ZUPREME-1 phase 2 dose-finding trial, the sponsor reported up to 10.7 percent mean body weight reduction at week 42 against 1.7 percent on placebo, and stated that at the maximally effective dose there were no cases of vomiting and no discontinuations from gastrointestinal adverse events. The company described tolerability as placebo-like and said it planned to move to phase 3.

The unknown

Everything peer review would normally settle: the full adverse-event table, discontinuation rates across all doses, how the completer analysis compares with intention-to-treat, and durability past 42 weeks. Whether the tolerability advantage over incretins survives a larger phase 3 population is the commercial and clinical question.

Our read

The most interesting non-GLP-1 obesity candidate in development, on evidence that is currently a press release. That is a real distinction and not a dismissal: phase 2 data reported by a sponsor is a reasonable basis for interest and a poor basis for conclusions. Worth watching for the paper.